Moore DH - Search Results

1

AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis.

Kim K, Moore DH, Makriyannis A, Abood ME. Kim K, et al. Among authors: moore dh. Eur J Pharmacol. 2006 Aug 7;542(1-3):100-5. doi: 10.1016/j.ejphar.2006.05.025. Epub 2006 May 20. Eur J Pharmacol. 2006. PMID: 16781706

2

Phase II/III randomized trial of TCH346 in patients with ALS.

Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, Moore D, Pohlmann H, Sauer D, Silani V, Strong M, Swash M, Vernotica E; TCH346 Study Group. Miller R, et al. Neurology. 2007 Aug 21;69(8):776-84. doi: 10.1212/01.wnl.0000269676.07319.09. Neurology. 2007. PMID: 17709710 Clinical Trial.

3

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group.

Miller RG, Moore D, Young LA, Armon C, Barohn RJ, Bromberg MB, Bryan WW, Gelinas DF, Mendoza MC, Neville HE, Parry GJ, Petajan JH, Ravits JM, Ringel SP, Ross MA. Miller RG, et al. Neurology. 1996 Dec;47(6):1383-8. doi: 10.1212/wnl.47.6.1383. Neurology. 1996. PMID: 8960715 Clinical Trial.

4

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Miller RG, Mitchell JD, Lyon M, Moore DH. Miller RG, et al. Among authors: moore dh. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):191-206. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003. PMID: 13129806 Review.

5

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Miller RG, Mitchell JD, Moore DH. Miller RG, et al. Among authors: moore dh. Cochrane Database Syst Rev. 2001;(4):CD001447. doi: 10.1002/14651858.CD001447. Cochrane Database Syst Rev. 2001. PMID: 11687111 Updated. Review.

6

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Miller RG, Mitchell JD, Moore DH. Miller RG, et al. Among authors: moore dh. Cochrane Database Syst Rev. 2000;(2):CD001447. doi: 10.1002/14651858.CD001447. Cochrane Database Syst Rev. 2000. PMID: 10796796 Updated. Review.

7

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis.

Miller RG, Moore DH 2nd, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, Bryan W, Ravits J, Yuen E, Neville H, Ringel S, Bromberg M, Petajan J, Amato AA, Jackson C, Johnson W, Mandler R, Bosch P, Smith B, Graves M, Ross M, Sorenson EJ, Kelkar P, Parry G, Olney R; Western ALS Study Group. Miller RG, et al. Among authors: moore dh 2nd. Neurology. 2001 Apr 10;56(7):843-8. doi: 10.1212/wnl.56.7.843. Neurology. 2001. PMID: 11294919 Clinical Trial.

8

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Miller RG, Mitchell JD, Lyon M, Moore DH. Miller RG, et al. Among authors: moore dh. Cochrane Database Syst Rev. 2002;(2):CD001447. doi: 10.1002/14651858.CD001447. Cochrane Database Syst Rev. 2002. PMID: 12076411 Updated. Review.

9

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design.

Miller RG, Moore DH, Forshew DA, Katz JS, Barohn RJ, Valan M, Bromberg MB, Goslin KL, Graves MC, McCluskey LF, McVey AL, Mozaffar T, Florence JM, Pestronk A, Ross M, Simpson EP, Appel SH; WALS Study Group. Miller RG, et al. Among authors: moore dh. Neurology. 2011 Sep 6;77(10):973-9. doi: 10.1212/WNL.0b013e31822dc7a5. Epub 2011 Aug 3. Neurology. 2011. PMID: 21813790 Free PMC article. Clinical Trial.

10

Effect of neuroprotective drugs on gene expression in G93A/SOD1 mice.

Ignacio S, Moore DH, Smith AP, Lee NM. Ignacio S, et al. Among authors: moore dh. Ann N Y Acad Sci. 2005 Aug;1053:121-36. doi: 10.1196/annals.1344.010. Ann N Y Acad Sci. 2005. PMID: 16179515

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results